Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
βETA PRESERVE teplizumab in recently diagnosed stage 3 type 1 diabetes
2024-519494-19-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Teplizumab with Matched placebo (2 arms). Planned start May 2025; status: authorised.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-519494-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519494-19-00.